Six cases of women with diethylstilbestrol in utero demonstrating long-term manifestations and current evaluation guidelines.
Diethylstilbestrol (DES), a nonsteroidal estrogen, was widely used in the United States from 1940 through 1971 to prevent pregnancy loss. In the late 1960s, an association was made with an increased incidence of clear cell adenocarcinoma in young women exposed in utero to DES. Additional study of these women over the next 35 years has shown an increased risk of other health problems including intraepithelial neoplasia, ectopic pregnancy, first trimester spontaneous abortion and second trimester pregnancy loss. The National Institutes of Health continues to fund studies to follow cohorts of DES-exposed mothers, daughters, sons and third generation children. The Centers for Disease Control have conducted a large DES Education Project and have established guidelines for management. The following six cases studies illustrate common problems seen in DES exposed daughters and management of problems encountered.
Tedeschi
Candice A
CA
CDC DES Education Project, Great Neck, NY, USA. candy@myway.com
Rubin
Mary
M
Krumholz
Burton A
BA
D018262:Adenocarcinoma, Clear Cell / Q000139:chemically induced; D000328:Adult; D004054:Diethylstilbestrol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced; D011271:Pregnancy, Ectopic / Q000139:chemically induced; D011297:Prenatal Exposure Delayed Effects; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced; D014625:Vaginal Neoplasms / Q000139:chemically induced; D002578:Uterine Cervical Dysplasia / Q000139:chemically induced
D004054:Diethylstilbestrol